Put companies on watchlist
DKSH Management Ltd.
ISIN: CH0126673539
WKN: A1JU9U
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

DKSH Management Ltd. · ISIN: CH0126673539 · EQS - Company News (54 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1814549
15 January 2024 07:00AM

DKSH Acquires Healthcare Distributor Medipharm in Brunei


DKSH Management Ltd. / Key word(s): Takeover
DKSH Acquires Healthcare Distributor Medipharm in Brunei

15.01.2024 / 07:00 CET/CEST


Media release

DKSH has signed an agreement to acquire Medipharm Sdn Bhd (“Medipharm”), one of the leading pharmaceutical and medical devices distributors in Brunei. With this acquisition, DKSH Healthcare grows its business in line with the strategy to expand its footprint in the Asia-Pacific region.

Zurich, Switzerland, January 15, 2024 – DKSH has announced today that it signed an agreement to acquire Medipharm, one of the leading pharmaceutical and medical devices distributors in Brunei. DKSH and Medipharm build on a longstanding strategic partnership, with Medipharm having operated as DKSH’s sub distributor in Brunei for the last 25 years.

Medipharm generates net sales of more than CHF 30 million1 at good profitability. With a team of over 50 people, the company serves renowned blue-chip clients. Medipharm distributes pharmaceutical products, medical devices, consumer health, personal care, and nutritional products. Its main customers are hospitals, medical centers, clinics, opticians, and pharmacies.

Bijay Singh, Head Business Unit Healthcare, said: “With the integration of Medipharm, and Brunei being one of the few markets in Asia-Pacific with no direct presence of DKSH Healthcare, we further increase our footprint, enabling us to provide even more encompassing market coverage for our clients. We warmly welcome all Medipharm employees at DKSH and look forward to continuing our longstanding, successful partnership.”

Pengiran Sharinah, Chairwoman of Medipharm, commented: "Since Medipharm was founded in 1998, we have acted as a pivotal intermediary between our clients and customers in the distribution of life-saving drugs and medical products. The combination with DKSH marks the next milestone in our company history and will equally benefit our clients, employees, and business partners. We look forward to building on our joint expertise and continuing to pursue our journey of growth.”

¹ Exchange rate 1 Swiss Franc / 1.5 Brunei Dollar

About DKSH 
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 37 markets with 32,600 specialists, generating net sales of CHF 11.3 billion in 2022. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,990 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2022. www.dksh.com/hec

For more information please contact:

DKSH Holding Ltd.

Till Leisner
Head, Group Investor & Media Relations
Phone +41 44 386 7315
till.leisner@dksh.com


Melanie Grüter
Manager Group Media Relations
Phone +41 44 386 7211
melanie.grueter@dksh.com 



End of Media Release


Language: English
Company: DKSH Management Ltd.
Wiesenstrasse 8
8008 Zurich
Switzerland
Phone: 044 386 72 72
E-mail: media@dksh.com
Internet: www.dksh.com
ISIN: CH0126673539
Valor: 12667353
Listed: SIX Swiss Exchange
EQS News ID: 1814549

 
End of News EQS News Service

1814549  15.01.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1814549&application_name=news&site_id=boersengefluester_html
Visual performance / price development - DKSH Management Ltd.
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.